<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2022</study_start_year><condition>Colorectal Neoplasms</condition><condition>Unresectable or Metastatic Colorectal Cancer</condition><disease>Colorectal Neoplasms</disease><disease>Unresectable Or Metastatic Colorectal Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/13708</full_dataset_link><location>China</location><study_start_month>8</study_start_month><repository>ECRIN MDR</repository><study_status>Recruiting</study_status></additional><is_claimable>false</is_claimable><name>FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ) in the Treatment of Unresectable or Metastatic Colorectal Cancer</name><description>To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen containing Levofolinic Acid (Zuoyu ) in first-line treatment of unresectable or metastatic colorectal cancer</description><dates><creation>2022-08-15</creation></dates><accession>13708</accession><cross_references><ClinicalTrials___gov>NCT05797883</ClinicalTrials___gov></cross_references></HashMap>